25th Congress of the APSR

Co-sponsored Seminars

• Luncheon Seminar 1

  Pathophysiology and treatment of COPD patients

  This presentation will discuss the pathophysiology and treatment of COPD. This will be especially based on the current situation in Asia including Japan.

  Chair: Kazuto Matsunaga (Department of Respiratory Medicine and Infectious Disease, Yamaguchi University, Japan)

  Speaker: Atsuyasu Sato (Department of Respiratory Medicine, Kyoto University, Japan)

  Speaker: Chin Kook Rhee (Seoul St. Mary’s Hospital, The Catholic University of Korea, Republic of Korea)

  Co-sponsored by Boehringer Ingelheim

• Luncheon Seminar 2

  Cancer Immunotherapy for NSCLC　～Thinking about the optimal first-line treatment～

  Immune checkpoint inhibitors (ICIs) such as anti-PD-1 antibodies: nivolumab and pembrolizumab, anti-PD-L1 antibody: atezolizumab, and anti-CTLA4 antibody; ipilimumab has been approved for advanced NSCLC patients. Additionally, the combination of cytotoxic chemotherapy with ICIs have showed the clinical benefit in several phase III trials. On the other hands, it remains unclear which ICIs and combination of cytotoxic chemotherapy with ICIs are the best first-treatment strategy for advanced NSCLC patients. This seminar will discuss the difference of ICIs (anti-PD-1 antibody and anti-PD-L1 antibody), and how to select ICIs as first-line treatment for advanced NSCLC patients.

  Chair: Terufumi Kato (Department of Thoracic Oncology, Kanagawa Cancer Center, Japan)

  Speaker: Tatsuya Yoshida (Department of Thoracic Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Japan)

  Co-sponsored by Chugai Pharmaceutical Co., Ltd.

• Luncheon Seminar 3

  Theme:COPD Treatment Strategy based on the latest study

  At this symposia, Dr. Ichiro Kuwahira will provide pathology of COPD, latest clinical evidence and clinical treatment strategy of COPD with Dr. Muro as a Chair. The participants will be able to understand the pathology, latest findings of clinical evidence including ETHOS and KRONOS post hoc analysis of Breztri and practical treatment strategy for COPD.

  Chair: Shigeo Muro (Nara Medical University, Department of Respiratory Medicine, Japan)

  Speaker: Ichiro Kuwahira (Tokai University Tokyo Hospital, Pulmonary Medicine, Japan)

  Co-sponsored by AstraZeneca K.K.

• Luncheon Seminar 4

  Type2 inflammation in asthma

  In many cases of asthma, type 2 cytokines (IL-4, IL-5, IL-13) produced by type 2 helper T cells (Th2) and type 2 innate lymphocytes (ILC2) induce so-called "type 2 inflammation", resulting in eosinophil-dominated airway inflammation. This leads to eosinophilic airway inflammation. Typical biomarkers of type 2 inflammation are sputum and peripheral blood eosinophils, exhaled nitric oxide (FeNO) and IgE. Although these biologics target type 2 inflammation, there is currently considerable debate as to which type 2 inflammatory markers are useful in predicting the efficacy of each drug, and their interpretation as biomarkers in the selection process requires further investigation. On the other hand, these biologics can be used to reduce or eliminate the use of oral steroids (OCS), which have been used as a last resort. We have also experienced cases of steroid refractoriness that has been difficult to treat with OCS and has responded well to biologics. By considering the pathogenesis of these cases in the future, we may be able to get closer to the essence of the pathogenesis of severe asthma. In this seminar, I would like to review the paradigm shift in asthma treatment with our findings and to outline the value of biologics.I will introduce the efficacy and safety of dupilumab for severe asthma patients.

  Chair: Koichiro Asano (Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan)

  Speaker: Koichi Fukunaga (Pulmonary Division, Department of Medicine, Keio University School of Medicine, Japan)

  Co-sponsored by Sanofi K. K.

• Luncheon Seminar 5

  Asthma New Treatment Pathway

  Lecture_1: Pharmacological management with LAMA in asthma patients

  The treatment with LAMA in asthma patients is supported by pharmacological and clinical evidence. It has been reported that triple therapy is effective for patients who have cough and sputum despite being treated with ICS/LABA.

  It is important to consider the types of patients who would benefit from triple therapy. Lecture_2：Anti-IL-5 Therapy for Severe Asthma – From Real World Data

  More than 5 years have passed since the introduction of anti-IL-5 antibody therapy for severe asthma into clinical practice. In this talk, I will introduce a real-world observational study that reconfirmed the main effects of suppressing exacerbations and reducing the amount of oral steroids used, with case presentations.

  Chair: Yuji Tohda (Kindai University Hospital, Japan)

  Speaker: Etsuko Tagaya (Respiratory Medicine, Tokyo Women's Medical University, Japan)

  Speaker: Takuro Sakagami (Respiratory Medicine, Kumamoto University, Japan)

  Co-sponsored by GlaxoSmithKline

• Coffee Break seminar 1

  Progressive fibrosing ILD: the world beyond IPF

  The presentation will discuss the progressive fibrosing ILDs beyond IPF. This will range from the overarching concept to the importance of an accurate diagnosis and the management strategies in clinical practice

  Chair: Yasuhiko Nishioka (Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Japan)

  Speaker: Martin Kolb (McMaster University and St. Joseph’s Healthcare, Hamilton, Ontario, Canada)

  Co-sponsored by Boehringer Ingelheim

• Coffee Break seminar 2

  Hospitalized COVID-19 Patients: Current Concepts in the Management

  The COVID -19 pandemic has significantly changed the healthcare system as well as lifestyle in all over the world. COVID-19 treatment has continued to progress since 2020 Several drug and vaccines have been approved but the pandemic situation will not settle down because of viral mutations. The most important clinical view of COVID-19 treatment is reducing mortality and preventing the progression of the disease by utilizing available options in appropriate setting or timing.

  Chair: Yohei Doi (Departments of Microbiology and Infectious Diseases, Fujita Health University Hospital, Japan)

  Speaker: David Alain Wohl (Institute of Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, USA)

  Co-sponsored by Gilead Sciences K.K

• Coffee Break Seminar 3

  New treatment strategies for driver mutation-positive NSCLC

  Lung cancer remains the leading cause of cancer-related mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) has led to the discovery of actionable oncogenic driver alterations, which has revolutionized treatment for this disease. Lung adenocarcinoma harboring such mutations can be treated with molecular- target agents.

  I would like to share the latest findings, focusing on the most frequently occurring EGFR mutation and RET fusion positive NSCLC where new treatment options are recently approved in Japan.

  Chair: Akihiko Gemma (Nippon Medical School, Japan)

  Speaker: Hidehito Horinouchi (Department of Thoracic Oncology National Cancer Center Hospital, Japan)

  Co-sponsored by Eli Lilly Japan K.K.

• Coffee Break Seminar 4

  BEST PRACTICES FOR RESPIRATORY SYNDROMIC TESTING IN COVID-19 ERA AND POST-COVID FUTURE

  A global leader in in vitro diagnostics for over 55 years, bioMérieux has always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. bioMérieux develops and produces in vitro diagnostic solutions for private and hospital laboratories, mainly for the diagnosis of infectious diseases. The results obtained from a patient sample provide doctors with information to support their decisions.

  BioFire Diagnostics is the leader in syndromic infectious disease testing, with more than 25 years of molecular experience and as bioMérieux’s Global Center of Excellence for Molecular Diagnostics, BioFire sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing.

  Chair: Yoshihiro Nishimura (Kobe University,Division of Respiratory Medicine, Japan)

  Speaker: Hitoshi Honda (Tokyo Metropolitan Tama Medical Center, Division of Infectious Disease, Japan)

  Co-sponsored by BIOMERIEUX

• Sponsored Symposium 1

  Progressive fibrosing interstitial lung diseases (PF-ILD) -Disease concept, Monitoring, Treatment.

  The presentation will discuss knowledge gaps in the disease concept, pathogenesis, and classification of patients with PF-ILD. This will be share knowledge of diagnosis / monitoring of actual medical practice of PF-ILD, and discuss current challenge and future medical care and will explore current approaches for PF-ILD, including the use of the antifibrotic therapy of nintedanib.

  Chairs: Takafumi Suda (Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Japan)
  Yoshikazu Inoue (Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan)

  Speaker: Yoshikazu Inoue (Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan)

  Speaker: Masataka Kuwana (Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan)

  Speaker: Vincent Cottin (National Reference Centre for Rare Pulmonary Diseases,　Louis Pradel University Hospital and Claude Bernard University, Lyon, France)Co-sponsored by Boehringer Ingelheim

• Sponsored Symposium 2

  Treatment Strategies for Achieving Asthma Management Goals

  It is important to maintain normal respiratory function and control the decline over time as well as symptoms and exacerbations in order to achieve the management goals of asthma. In the pathology of asthma, IL-4 and IL-13 are involved in Th2 cell differentiation, tissue migration of eosinophils, IgE production by B cell class switching, airway contraction and remodeling, and mucus production. In addition, group 2 innate lymphoid cells (ILC2s), basophils, and macrophages are involved in type 2 immune response by innate immunity, and these cells cross-talk with each other via IL-4 and IL-13. Therefore, dupilumab has been expected to suppress type 2 immune responses broadly by inhibiting both innate and acquired immune cascades. In this lecture, we will discuss the latest advancement of asthma pathology and usefulness of dupilumab.

  Chairs: Hiromasa Inoue (Department of Pulmonary Medicine, Kagoshima University, Japan)
  Masakazu Ichinose (Academic Center of Osaki Citizen Hospital, Japan)

  Speaker: Koichiro Takahashi (Division of Respiratory Medicine, Saga University Hospital, Japan)

  Speaker: Hiroki Kabata (Division of Pulmonary Medicine, Department of Medicine, Keio University school of Medicine, Japan)

  Speaker: Kazuto Matsunaga (Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Japan)Co-sponsored by Sanofi K. K.

• Sponsored Symposium 3

  Solving Social Problems through Partnerships between Medicine and Industry

  Japan Clean Air Association and Nikkeisha, Inc. Joint Seminar;

  Solving Social Issues through Partnership between Medical and Industrial Sectors (11/20 (Sat) 18:00~19: 30, 90min, presented in Japanese with simultaneous interpretation in English)

  Chair: Shu Hashimoto (President, Japan Clean Air Association; President, 25th APSR Congress)

  Speaker: Shu Hashimoto (President, Japan Clean Air Association; President, 25th APSR Congress)

  Speaker: Tsuyako Nakamura (Professor, Faculty of Global Communication, Doshisha University)

  Speaker: Yuichi Yamazaki (General Manager, Precision Equipment Business Unit, Kubota Corporation)

  Speaker: Katsunori Yanagihara (Professor, Nagasaki University Graduate School of Biomedical Sciences Head, Laboratory Medicine, Nagasaki University Hospital)

  Speaker: Atsushi Suzuki (Director,Economic Sustainability Consortium)

  Speaker: Keisuke Kurose (Japan Clean Air Association)Co-sponsored by Japan Clean Air Association and Nikkeisha, Inc.

• Sponsored Symposium 4

  Current Status and Future Perspectives of Treatment Strategy in Lung Cancer （NSCLC/SCLC）

  At this symposia, speakers will provide clinical practice on the optimal treatment strategy in unresectable lung cancer patients

  From Dr. Niels Reinmuth
  Through the findings from the CASPIAN clinical trial results, lecture will be shared the clinical experience with Imfinzi in ES-SCLC patients.

  From Dr. Myung-Ju Ahn
  Focusing on driver gene mutation NSCLC in stage IV
  * Current status of biomarker testing when selecting 1st line treatment
  * Highlights of guidelines for EGFR / ALK NSCLC treatment strategy
  * Osimertinib's clinical experience for stage IV EGFRm + NSCLC

  Chair: Kazuhisa Takahashi (Juntendo University Hospital, Juntendo University Faculty of Medicine & Professor and Chairman, Graduate School of Medicine Division of Respiratory Medicine, Japan)

  Speaker: Niels Reinmuth (Department of Pulmonary Oncology, Asklepios Lung Clinic Munich-Gauting Gauting, Germany)

  Speaker: Myung-Ju Ahn (Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Republic of Korea)Co-sponsored by AstraZeneca K.K.

• Sponsored Symposium 5

  Endobronchial Ultrasound in Asia – Past, Present and Future

  Since the introduction of the world’s first curved linear array ultrasonic bronchoscope by Olympus in 2004, EBUS-TBNA has been widely accepted as the gold standard for lung cancer staging and is complemented by radial EBUS for peripheral. With the increasing adoption of EBUS, this symposium aims to review the growth, practice, and challenges of EBUS in Asia over the years and the expectations for the future.

  Chairs: Noriaki Kurimoto (Shimane University Hospital, Japan)
  David Fielding (Royal Brisbane and Women’s Hospital, Australia)

  Speaker: Noriaki Kurimoto (Shimane University Hospital, Japan)

  Speaker: Jung Seop Eom (Pusan National University Hospital, Republic of Korea)

  Speaker: Anan Wattanathum (Phramongkutklao Hospital, Bangkok)

  Speaker: Wahju Aniwidyaningsih (Persahabatan Hospital, Indonesia)

  Speaker: David Fielding (Royal Brisbane and Women’s Hospital, Australia)Co-sponsored by Olympus Corporation

• Sponsored Symposium 6

  Treatable Traits approach for the management of obstructive airways diseases

  ‘Treatable Traits’ is becoming an increasingly recognized paradigm for the treatment of airways diseases, affording identification of unique characteristics with the potential to enable improved therapy tailored to individual needs of each patient. Through the course of this symposium, the audience will learn about the Treatable Traits approach and evidence to date for its application in obstructive airways diseases, the upcoming Treatable Traits study in Japan and also consider cases of COPD and asthma within the Treatable Traits framework and recommended management with application for daily practice.
  -Welcome and introduction
  Introduction to Treatable traits
  Using Treatable traits in clinical practice
  Cases: Traits in action
  Q & A and wrap up

  Chair: David Leather (GlaxoSmithKline Global Medical, UK)

  Speaker: Neil Barnes (GlaxoSmithKline Global Medical, UK)

  Speaker: Alvar Agusti (Medicine, University of Barcelona, Spain)

  Co-sponsored by GlaxoSmithKline

• Meet the Expert 1

  IPF practice based on guidelines and experience in Japan

  The presentation will share knowledge and tips on IPF treatment based on evidence / guidelines from Experts with extensive experience in IPF treatment. After the presentation, there will be a discussion on the IPF treatment gap between Japan and Asian countries and consider appropriate treatment or IPF patients.

  Chair: Masashi Bando (Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan)

  Speaker: Yasuhiro Kondoh (Deputy Director, Department of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan)

  Co-sponsored by Boehringer Ingelheim

• Meet the Expert 2

  Remaining challenges of biologics in severe asthma treatment

  At this symposia, Dr. Hisako Matsumoto will provide latest evidence and clinical treatment strategy of biologics in severe asthma treatment with Dr. Yokoyama as a Chair. Lecture from Dr. Hisako Matsumoto will focus on the findings from the latest evidence on biologics treatment in severe asthma. The lecture will also share the importance of eosinophil depletion, zero exacerbation and zero OCS in severe asthma patients.

  Chair: Akihito Yokoyama (Kochi Medical School, Kochi University, Japan)

  Speaker: Hisako Matsumoto (Kindai University Faculty of Medicine

  )Co-sponsored by AstraZeneca K.K.

• Meet the Expert 3

  Airway obstruction in asthma

  This session will be focused on the current state of respiratory treatment in Japan and the importance of airflow obstruction in asthma.

  Chair: Hiromasa Inoue (Kagoshima University Department of Pulmonary Medicine, Graduate school of Medical and Dental Sciences, Japan)

  Speaker: Kazuto Matsunaga (Yamaguchi University Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Japan)

  Co-sponsored by Novartis Pharma K.K.

• Meet the Expert 4

  Current research aimed at overcoming clinical questions of thoracic malignancies

  The diagnosis and treatment of thoracic malignancies have been developed dramatically in recent decades. However, there are still lots of problems to be solved. The presenter is going to talk about his current research which is aiming at overcoming clinical questions of thoracic malignancies, especially in the field of rare thoracic tumors and cancer cachexia. After the lecture, the presenter would be happy if he could discuss with the audience how to detect/generate/solve clinical questions in the field of thoracic malignancies.

  Chair: Sakae Honma (Toho University Department of Advanced and Integrated Interstitial Lung Diseases Research, Japan)

  Speaker: Takehito Shyukuya (Juntendo University Department of Respiratory Medicine, Japan)

  Co-sponsored by TAIHO PHARMACEUTICAL CO., LTD.

• Meet the Expert 5

  Comprehensive Genomic Profiling for non-small cell lung cancer treatment

  Comprehensive Genomic Profiling (CGP) including FoundationOne and FoundationOne-Liquid is a system based on next-generation sequencing, which can explore hundreds of genomic alterations in tumor or plasma from patients with various types of cancer. The system has been approved and widely used for clinical practice under health-care re-imbursement in Japan. Targeted-sequencing and multiplex PCR testing are also approved for screening the driver oncogenes of non-small cell lung cancer in Japan. The significance and role of CGP testing as well as the profits of tissue or plasma CGP for lung cancer treatment will be discussed.

  Chair: Naoko Aragane (Department of Respiratory Medicine, Saga University Hospital/Saga University Hospital Cancer Center, Japan)

  Speaker: Eiji Iwama (Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan)

  Co-sponsored by Chugai Pharmaceutical Co., Ltd.

• Sponsored Lecture 1

  Multi-disciplinary strategies to improve lung cancer treatment

  Recent genome information-guided precision medicine approaches improved the prognosis of lung cancer patients. However, even in EGFR-mutated lung cancer, one of the best-studied subgroups of lung cancer, there are many problems to be solved. In this presentation, I will talk about the limitation of current precision medicine approaches in lung cancer and propose the importance of multi-disciplinary strategies including the development of cytotoxic agents to improve the prognosis of lung cancer patients.

  Chair: Kazuhisa Takahashi (Juntendo University Department of Respiratory Medicine, Japan)

  Speaker: Hiroyuki Yasuda (Keio University Division of Pulmonary Medicine, Japan)

  Co-sponsored by TAIHO PHARMACEUTICAL CO., LTD.

• Sponsored Lecture 2

  The current role of ICI in NSCLC Treatment

  Since Pembrolizumab monotherapy was approved for the patients with PD-L1≥50% in Dec in 2016, ICI became one of the based drug for NSCLC treatment. For 1st line setting, anti-PD-1/L1 monotherapy, anti-PD-1/L1 combination with chemotherapy and Ipilimumab plus Nivolumab±chemotherapy are currently available in both histology and are prescribed according to the PD-L1 expression on tumor cells in Japan.

  I’ll present the latest evidence for each regimen and the role of ICI in clinical practice for NSCLC treatment in this lecture.

  Chair: Isamu Okamoto (Research Institute for Diseases of the Chest Graduate School of Medical Sciences, Kyushu University, Japan)

  Speaker: Kentaro Tanaka (Department of Respiratory Medicine, Kyushu University Hospital, Japan)

  Co-sponsored by MSD K.K.

• Sponsored Lecture 3

  Selection of inhaled medications based on asthma symptoms

  This session will be discussed importance of LAMA in asthma treatment and positioning of ENERZAIR from clinical trials and experiences.

  Chair: Takeshi Kaneko (Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan)

  Speaker: Hisako Matsumoto (Kindai University Faculty of Medicine, Department of Respiratory Medicine & Allergology, Japan)

  Co-sponsored by Novartis Pharma K.K.

• Sponsored Lecture 4

  Biomarker-Driven Therapy for NSCLC: Focus on ALK

  In NSCLC, optimal treatment is put into practice with subdividing patients with genetic alterations and protein expression. Biomarker driven treatment started from EGFR which drug development preceded the biomarker discovery. Since then, finding the target and subsequently investigate the optimal medicine is the standard of biomarker driven oncology. These are best exemplified by ALK and ROS1 altered patients in NSCLC. In this lecture, I will review the developmental process of ALK and ROS1 treatment. Both patients consists of small portion of total NSCLC, but small differences in number is making the developmental strategies different.

  Chair: Makoto Nishio (Thoracic Medical Oncology Department, Cancer Institute Hospital of JFCR, Japan)vYasushi Goto (Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

  Co-sponsored by Chugai Pharmaceutical Co., Ltd.

• Sponsored Lecture 5

  Updates in Asthma : Device, Drug & Disease

  Even on optimal therapy, real-life control of asthma is still unsatisfactory. Asthma control as defined by the Global Initiative for Asthma (GINA) criteria was low in Asia similarly to the results reported in Europe. This presentation will give updates on the current problem of asthma control, preferred use of inhaled corticosteroids specified in asthma guidelines, inhaler choice and technique, pathology and treatment of small airways, and clinical outcomes of patients treated with fluticasone propionate and formoterol fumarate hydrate (FP/FORM) by inhalation using a pressurized metered-dose inhaler (pMDI) device.

  Chair: Akio Niimi (Nagoya City University Graduate School of Medical Sciences, Department of Respiratory Medicine, Allergy and Clinical Immunology, Japan)

  Speaker: Omar S Usmani (Imperial College London, UK)

  Co-sponsored by Kyorin Pharmaceutical Co., Ltd.

• Sponsored Lecture 6

  Progress of the treatment for squamous cell lung cancer in Japan

  Target Audience: Clinicians, Researchers, Oncologist, Fellows and residents in training.

  Objectives
  1. review the transition of the treatment strategy for squamous cell lung cancer (SQ) in Japan.
  2. examine the treatment for SQ in the countries where some new drugs, e.g. immune checkpoint inhibitors (ICIs), are not usable.

  Summary
  ICIs are used for primary treatment for SQ widely currently in Japan. In addition, we also obtained the anti-EGFR antibody medicine. The speaker, Dr. T. Kato, review the therapeutic strategy for SQ in Japan. In addition, He will introduce the history of the development of the anti-cancer drugs for lung cancer, especially for SQ. However, the countries where new medicines such as ICIs are not approved exist in Asia. He will introduce the treatment strategy for SQ in such countries.

  Chair: Yuichiro Ohe (Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

  Speaker: Terufumi Kato (Department of Thoracic Oncology, Kanagawa Cancer Center, Japan)

  Co-sponsored by Nippon Kayaku Co., Ltd.

• Sponsored Lecture 7

  Role of LAMA in asthma treatment

  Theme of Seminar: New treatment options for airway inflammation and air passage obstruction in asthma

  Summary：
  In Hokkaido COPD cohort study, bronchodilator response (BDR) by beta2-agonist and anticholinergics had been evaluated alternately every 6 months, This unique protocol made it possible to compare the BDRs by two agents for all subjects. In this seminar, based on the results of our cohort study, we would like to discuss the rationale for the combination use of two different bronchodilators (beta2-agonist and anticholinergics) for management of chronic airway diseases, such as asthma and COPD.

  Chair: Takeshi Kaneko (Respiratory Medicine, Yokohama City University, Japan)

  Speaker: Satoshi Konno (Respiratory Medicine, Hokkaido University, Japan)

  Co-sponsored by GlaxoSmithKline

• Sponsored Lecture 8

  Airway Clearance Management with Oscillatory Airway Clearance Therapy on COVID Patients
  COVID RESPIRATORY CARE-Addressing Sputum and Airway Clearance

  In patients with critically ill COVID-19 pneumonia, lower airways are filled with plenty of highly viscous exudates or mucus, leading to airway occlusion or even a high case of fatality rate. Hence, controlling the airway clearance of severely ill COVID-19 patients is one of the most important targets of COVID-19 treatment.

  In this lecture, the attendees will gain insights into the clinician’s and patient’s perspectives on the benefits of High-Frequency Oscillation Therapy on COVID-19 respiratory care and appreciate the ability to program therapy specific to patient and ease of use High-Frequency Oscillation Therapy.

  Speaker: Huiqing Ge (Department of Respiratory Therapy, Sir Run Run Shaw Hospital affiliated to ZheJiang University Medical College Hospital, China)

  Speaker: Alexander Michael (Division of Pulmonary and Critical Care Medicine in Northwestern Medical Group, Illinois, USA)

  Co-sponsored by Hill-Rom Services Pte Ltd

• Sponsored Lecture 9

  Lung Cancer - Access and Ablation

  Chairs: Lam Bing (Hong Kong Sanatorium & Hospital, Hong Kong)
  Lee Pyng (National University Hospital, Singapore)

  Speaker: Terence Tam (Queen Mary Hospital, Hong Kong)

  Speaker: Shiyue Li (The First Affiliated Hospital of Guangzhou Medical University, China)

  Speaker: Daniel Steirfort (Royal Melbourne Hospital, Australia)

  Co-sponsored by Broncus Medical

• Sponsored Lecture 10

  The validity of the oxygen inhalation for severe COVID-19 patients and home oxygen therapy in China

  Daikin has been working to promote home oxygen therapy in China for about 10 years.

  In this seminar, we will report on the following two topics.

  The validity of the oxygen inhalation for severe COVID-19 patients．

  We will report with data that oxygen inhalation is an effective and is their essential therapy for severe COVID-19 patients.

  2．Home oxygen therapy ,our activity for apply to the public medical insurance in China.

  In China, we are currently working to promote proper oxygen inhalation for COPD patients. We will report on our activities and their progress.

  Chair: Shu Hashimoto (Nihon University, Japan)

  Speaker: Yuanlin Song (Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai)

  Speaker: Satoshi Ueda (DAIKIN MEDICAL TECHNOLOGY (SUZHOU)CO.,LTD, Japan)

  Co-sponsored by DAIKIN MEDICAL TECHNOLOGY (SUZHOU)CO.,LTD

• Sponsored Lecture 11

  Landscape of ICI treatment in NSCLC and its pitfall

  Immune checkpoint inhibitors (ICIs) have been approved and used as one of the regimens in the first-line treatment of non-small cell lung cancer (NSCLC). In addition, combination of ipilimumab and nivolumab with or without chemotherapy is available. Variety of treatment options are ready, but process of choosing those are becoming more and more complicated. In this lecture, we will review the evidence of those options and consider the proper use of those treatments.

  Chair: Makoto Nishio (Thoracic Medical Oncology Department, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan)

  Speaker: Yasushi Goto (Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

  Co-sponsored by MSD K.K.

• Sponsored Lecture 12

  Effects of biologics on Type 2 Inflammation in Severe Asthma

  Type 2 inflammatory airway co-morbidities, including CRSwNP, allergic rhinitis, and other diseases, are frequent and can add substantially to the symptom burden and quality of life impairment of patients with severe asthma.

  Anatomic, epidemiologic, pathophysiologic, and clinical treatment evidence support the united airways concept of a close association between diseases of the upper (allergic rhinitis and CRS/CRSwNP) and lower (asthma) airways.

  Common type2 inflammatory cells and mediators are involved in driving chronic upper and lower inflammatory airway diseases. Th2 cells and ILC2 initiate the type2 response cascade leading to the release of further response mediators, including the interleukins IL-4, IL-13, and IL-5, and eosinophils.

  Dupilumab is a human monoclonal antibody that blocks the cytokines IL-4 and IL-13, which are central to type 2 inflammation.

  I will introduce the efficacy and safety of dupilumab for severe asthma patients.

  Chair: Akio Niimi (Graduate School of Medical Sciences Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University, Japan)

  Speaker: Toshiyuki Koya (Department of Respiratory Medicine and Infectious Diseases, Niigata University Medical & Dental Hospital, Japan)

  Co-sponsored by Sanofi K. K.

• Sponsored Lecture 13

  Evidence of coil embolization for hemoptysis

  Two experts will give a lecture on Bronchial Artery Embolization (BAE) in hemoptysis treatment, such as current status of hemoptysis in Japan and various evidences including outcomes of BAE from their facilities. They will also introduce safety and efficacy of using coils for BAE which can contribute to the avoiding complications such as spinal infarction and recanalization of embolized arteries.

  Chair: Hideo Ishikawa (Hemoptysis and Pulmonary-Circulation Center, Eishinkai Kishiwada Rehabilitation Hospital, Japan)
  Yoshihisa Kodama (Department of Radiology, Teine Keijinkai Hospital, Japan)

  Speaker: Hideo Ishikawa (Hemoptysis and Pulmonary Circulation Center, Eishinkai Kishiwada Rehabilitation Hospital, Japan)

  Co-sponsored by Terumo Coporation

• Sponsored Lecture 14

  Treatment of Severe Eosinophilic Asthma with anti IL-5 antibody

  Eosinophilic inflammation plays an important role in the pathophysiology of severe asthma. IL-5 is the major cytokine for eosinophil activation, and IL-5-targeting treatment with mepolizumab has a highly clinical efficacy on severe eosinophilic asthma. Therefore, analysis of airway inflammation in patients with severe asthma using induced sputum is extremely important in the practice of tailor-made treatment. However, recent studies on the eosinophil subtypes have led to the accumulation of findings on the heterogeneity of eosinophil functions. In the future, new treatment strategies on the basis of eosinophil subtypes will be expected.

  Chair: Hiromasa Inoue (Pulmonary Medicine, Kagoshima University, Japan)

  Speaker: Hiroshi Kanazawa (Respiratory Medicine, Osaka City University, Japan)

  Co-sponsored by GlaxoSmithKline

• Sponsored Lecture 15

  Optimizing treatment for ALK-positive non-small cell lung cancer in 2021: a focus on Brigatinib.

  The theme of this seminar is “Treatment for ALK+ NSCLC”.

  Prof. Seike from Nippon Medical University and Dr. Zenke from National Cancer Center East hospital will be the chairperson and the speaker of the seminar, respectively.

  Brigatinib is a new generation ALK inhibitor with 1st line and 2nd line+ indication. Clinical data and Adverse event management of brigatinib will be presented, and the positioning of brigatinib in ALK+ NSCLC will be discussed in this seminar.

  Chair: Masahiro Seike (Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan)

  Speaker: Yoshitaka Zenke (Department of Thoracic Oncology, National Cancer Center Hospital East, Japan)

  Co-sponsored by Takeda Pharmaceutical Company Limited.

• Sponsored Lecture 16

  Challenges and Innovations in AI Technology for Respiratory Disease Imaging - From Data Acquisition and Processing to Interpretation

  Chest CT is widely used to evaluate structural alteration of airways and parenchyma in lung diseases such as COPD and IPF. In COPD, low attenuation area percent is a standard emphysema index associated with clinical outcomes such as lung function decline and prognosis. An accurate airway segmentation has also enabled quantifying the airway tree morphology three-dimensionally using airway-to-lung volume ratio, total airway count, and airway fractal dimension. In IPF, a recently-introduced AI-based quantitative CT (AIQCT) has enabled the segmentation of radiological abnormalities such as reticulation and honeycombing. These techniques augment the clinical relevance of chest imaging for improved disease management.

  Chair: Shigeo Muro (Department of Respiratory Medicine, Nara Medical University, Japan)

  Speaker: Hisaya Hagiwara (Image Diagnostics Sales Department, Diagnostic Systems Sales Division, FUJIFILM Healthcare Corporation, Japan)

  Speaker: Kozue Ito (IT Solution Division, Medical Business Division, FUJIFILM Corporation, Japan)

  Speaker: Naoya Tanabe (Department of Respiratory Medicine, Kyoto University, Japan)

  Co-sponsored by FUJIFILM Healthcare Corporation

• Sponsored Lecture 17

  New Era of Bronchoscopy

  The field of bronchoscopy is advancing rapidly. New technology, tools and techniques have been introduced to allow early detection and improve diagnostic yield. This lecture aims to address the current diagnostic challenges associated with peripheral lung lesion and the developments in this area. Recent advancements and new imaging technologies in bronchoscopy will also be introduced.

  Chair: Fumihiro Asano (Gifu Prefectural General Medical Center, Japan)

  Speaker: Yuji Matsumoto (National Cancer Center Hospital, Japan)

  Speaker: Vallandramam R. Pattabhi Raman (Royal Care Super Specialty Hospital, India)

  Co-sponsored by Olympus Corporation

• Sponsored Lecture 18

  The Current Status of Dual-Immunotherapy in Non-Small Cell Lung Cancer Treatment

  Checkpoint inhibitor plus/minus chemotherapy has been a standard of care for 1st line non-small cell lung cancer. Recently, the combination of Nivolumab and Ipilimumab plus/minus chemotherapy was approved in November 2020 in Japan and can be used in daily clinical practice. In this session, the role of CTLA-4 in the treatment of non-small cell lung cancer from the basic science perspective and the clinical benefit of the combination of Nivolumab and Ipilimumab plus/minus chemotherapy, especially the clinical study result of CM227 and CM9LA, will be discussed.

  Chair: Hirotsugu Kenmotsu (Division of Thoracic Oncology, Shizuoka Cancer Center, Japan)

  Speaker: Satoru Miura (Department of Internal Medicine, Niigata Cancer Center Hospital, Japan)

  Co-sponsored by Bristol Myers Squibb ONO PHARMACEUTICAL CO., LTD

• Sponsored Lecture 19

  Updates in Immunotherapy for First-Line Treatment of NSCLC

  First-line treatment in non-small cell lung cancer, immune checkpoint inhibitors (ICIs) may have durable response, however, their response are limited. To improve outcomes, combination therapy with chemotherapy has been tried. Recently, combination with anti-CTLA-4 antibody has been approved, and treatment options are expanding. In addition, long-term follow-up data has been reported in some clinical trials. In this lecture, we will consider first-line treatment while understanding current evidence and characteristics of monotherapy and combination therapy.

  Chair: Kazuhiko Nakagawa (Department of Medical Oncology, Kindai University, Faculty of Medicine, Japan)

  Speaker: Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

  Co-sponsored by MSD K.K.

• Sponsored Lecture 20

  Patient-centred inhaler device selection

  In this lecture, Professor Usmani will highlight the importance of selecting the right type of inhaler device for each patient: while DPI may be a good choice for some patients, it may not always be the best option - especially for the very young, the very old and the very ill -. While sharing his experience of asthma treatment in the UK, Professor Usmani will guide us through an overview of publications from around the world and emphasize the importance of patient inhalation technique, as well as the role that AeroChamber has to play in improving lung delivery.

  Chair: Akio Niimi (Nagoya City University Graduate School of Medical Sciences Department of Respiratory Medicine, Allergy and Clinical Immunology, Japan)

  Speaker: Omar Usmani (National Heart and Lung Institute,Imperial College London, UK)

  Co-sponsored by Trudell Medical International